CD274 and malignant colon neoplasm: Furthermore, treatment with the CDK4/6 inhibitor palbociclib in syngeneic colon cancer mouse models not only increased PD-L1 protein expression but also synergized with anti-PD-1 therapy, enhancing therapeutic efficacy.